VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Weber on Next Steps With Pembrolizumab as Melanoma Treatment

Jeffrey S. Weber, MD, PhD
Published: Friday, Jun 30, 2017



Jeffrey S. Weber, MD, PhD, a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the next steps with the PD-1 inhibitor pembrolizumab (Keytruda) as treatment for patients with melanoma.

Two of the most interesting studies that the community is excited about are the phase III trials of pembrolizumab combined with talimogene laherparepvec (Imlygic; T-VEC) and pembrolizumab with the IDO inhibitor epacadostat. The results of the pembrolizumab/epacadostat trial will likely be read out within the year, Weber explains.

If the study is positive, this then brings up the issue of what to do when patients fail on treatment. Moreover, if pembrolizumab/epacadostat becomes a frontline treatment of choice, then researchers will have to start thinking about potential combinations with ipilimumab.


Jeffrey S. Weber, MD, PhD, a medical oncologist and deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the next steps with the PD-1 inhibitor pembrolizumab (Keytruda) as treatment for patients with melanoma.

Two of the most interesting studies that the community is excited about are the phase III trials of pembrolizumab combined with talimogene laherparepvec (Imlygic; T-VEC) and pembrolizumab with the IDO inhibitor epacadostat. The results of the pembrolizumab/epacadostat trial will likely be read out within the year, Weber explains.

If the study is positive, this then brings up the issue of what to do when patients fail on treatment. Moreover, if pembrolizumab/epacadostat becomes a frontline treatment of choice, then researchers will have to start thinking about potential combinations with ipilimumab.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x